Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.51 |
| ▸ | CDK1 | P06493 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380633 | 0.85 | CDK1 (0.62) | CYP3A4MAPK1ALOX15CDK1ALDH1A1 | |
| SCHEMBL13866472 | 0.85 | CDK1 (0.62) | CYP3A4MAPK1ALOX15CDK1ALDH1A1 | |
| SCHEMBL14400799 | 0.83 | CDK1 (0.48) | CYP3A4MAPK1ALOX15CDK1ALDH1A1 | |
| SCHEMBL4462535 | 0.83 | CDK1 (0.44) | CYP3A4MAPK1TSHRALOX15CDK1 | |
| SCHEMBL4464767 | 0.83 | CDK1 (0.47) | CYP3A4MAPK1TSHRALOX15CDK1 | |
| SCHEMBL8353441 | 0.83 | CDK1 (0.44) | CYP3A4MAPK1TSHRALOX15CDK1 | |
| SCHEMBL8353775 | 0.81 | CDK1 (0.44) | CYP3A4MAPK1TSHRALOX15CDK1 | |
| SCHEMBL8353365 | 0.80 | CDK1 (0.42) | CYP3A4MAPK1TSHRALOX15CDK1 | |
| SCHEMBL4564902 | 0.80 | CDK1 (0.46) | CYP3A4MAPK1TSHRALOX15CDK1 | |
| SCHEMBL4458806 | 0.79 | PDE4A (0.49) | CYP3A4MAPK1TSHRALOX15CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528252-B2 | Derivatives of triazoly-imidazopyridine useful as ligands of the adenosine A2a receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-05-05 | — | — | US | disclosed |
| US-7528252-B2 | Derivatives of triazoly-imidazopyridine useful as ligands of the adenosine A2a receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-05-05 | — | — | US | disclosed |
| US-7528252-B2 | Derivatives of triazoly-imidazopyridine useful as ligands of the adenosine A2a receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-05-05 | — | — | US | disclosed |
| US-20070249638-A1 | Derivatives of triazoly-imidazopyridine and of the triazolypurines useful as ligands of the adenosine A2a receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-10-25 | — | — | US | disclosed |
| US-20070249638-A1 | Derivatives of triazoly-imidazopyridine and of the triazolypurines useful as ligands of the adenosine A2a receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-10-25 | — | — | US | disclosed |
| US-20070249638-A1 | Derivatives of triazoly-imidazopyridine and of the triazolypurines useful as ligands of the adenosine A2a receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-10-25 | — | — | US | disclosed |
| US-7230102-B2 | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-06-12 | — | — | US | disclosed |
| US-7230102-B2 | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-06-12 | — | — | US | disclosed |
| US-7230102-B2 | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-06-12 | — | — | US | disclosed |
| EP-1412354-B1 | DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A 2a? RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA TAU IND FARMACEUTI (IT) | 2006-05-10 | — | — | EP | disclosed |
| US-20040204428-A1 | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249638-A1 | Derivatives of triazoly-imidazopyridine and of the triazolypurines useful as ligands of the adenosine A2a receptor and their use as medicaments | ADORA3, ADORA2A, ADORA1 | CYP3A4 477/4885MAPK1 1146/4885TSHR 28/4885 |
| US-20040204428-A1 | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments | ADORA2A, ADORA1, ADORA3 | CYP3A4 1778/4885MAPK1 2748/4885TSHR 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.